

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7211888
<b>Application Number:</b>	10652814
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2748
<b>Title of Invention:</b>	Nanocapsule encapsulation system and method
<b>First Named Inventor/Applicant Name:</b>	Gretchen M. Unger
<b>Customer Number:</b>	25871
<b>Filer:</b>	Mary Breen Smith.
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	0269.01/C
<b>Receipt Date:</b>	15-MAR-2010
<b>Filing Date:</b>	29-AUG-2003
<b>Time Stamp:</b>	18:55:56
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$735
RAM confirmation Number	5264
Deposit Account	195117
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

**File Listing:**

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS_12_2010-03-15.pdf	118363 97d48f548041319d1c96cea7be56749cdc3 7a489	yes	4

**Multipart Description/PDF files in .zip description**

	Document Description	Start	End
	Transmittal Letter	1	2
	Information Disclosure Statement (IDS) Filed (SB/08)	3	4

**Warnings:****Information:**

2	Foreign Reference	WO_2008_095192.pdf	3310726 27b1590758974df01900ec6996e4a2ed684 a9e85	no	57
---	-------------------	--------------------	---	----	----

**Warnings:****Information:**

3	Foreign Reference	WO_2008_157514.pdf	2045776 ac62267f170d63adfb35d84445357e6008c 0c2c8	no	20
---	-------------------	--------------------	---	----	----

**Warnings:****Information:**

4	NPL Documents	Cook_1998_Antisense_Med_Chem_51_.pdf	11130949 29b90dd992a3807f5ded9ca10ae892e3bdb c5824	no	50
---	---------------	--------------------------------------	--	----	----

**Warnings:****Information:**

5	NPL Documents	Dresser_2001_AAPS_Pharm_Sci_3_3.pdf	52100 5f92e0a943615fc8e052c9d9f7b14d3a22db 23c6	no	3
---	---------------	-------------------------------------	---	----	---

**Warnings:****Information:**

6	NPL Documents	Kibbe_EDHandbook_Pharm_Exipients_3ED_pp94-95.pdf	708879 b0b02c2e0640ee4321821442f9d3bb28adb 0ee08	no	8
---	---------------	--	--	----	---

**Warnings:****Information:**

7	NPL Documents	Halin_2002_Nature_Biotech_20_264.pdf	1708504 0f070dcaa7f4e1b3353ea8d794ca8d5e1d7 d992b	no	6
---	---------------	--------------------------------------	---	----	---

**Warnings:****Information:**

8	NPL Documents	Heidel_2005_Adv-Biochem-Eging_v99_7-39.pdf	731764 dbe81348b18b7c9e4bf003220f22b735c37 481e0	no	33
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Kong_2000_Cancer_Research_v10_4440-4445.pdf	311479 45c62da1e5b1bd76ba0d8c6e9a1500c0860 5594b	no	6
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Nagano_1993_Glia_8_71.pdf	1495097 a67a372a279cb84d81f77e039f9885a06fa5 14e9	no	6
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Schneider_1999_FEBS_458_32_9-32.pdf	117194 e5ef176ba87009f160b5c8c9d13c955e0450 4682	no	4
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Smith_Ho_1972_J-Org-Chem_v37_653-656.pdf	478562 1d41ede827ac58fb3ede188ca19944c9536 4246	no	4
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Summerton_1997_Antisense_Nuc_Acid_Drug_Devel_7_187.pdf	3739083 6665e41ec6ff8b9c0e16d1e3ca60451328e8 6646	no	9
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Wang_2006_J_Cell_Biochem_9_382.pdf	202731 abaaa868cd7f8969973ba55a67e3bd91fa5 49d85	no	10
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Wong_1991_CRC_Press_Tbl_Contents.pdf	22278707 0f11a2598510fd16c35f271696fb92475fe4c 7a1	no	9
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Yamamoto_1999_J_Biol_Chem_214_21840.pdf	274666 eca73b2409920489728a6ed76b14e156966 a777a	no	7
<b>Warnings:</b>					
<b>Information:</b>					

17	NPL Documents	Yuan_1994_Cancer_research_5 4-3352.pdf	590026 7e8d111083c7a7fe27f97127ce5e5fa04070 30e8	no	5					
<b>Warnings:</b>										
<b>Information:</b>										
18	NPL Documents	Zhang_1997_Journal_Appl_Toxicology_17_247.pdf	732265 ab542a0c4dc94c5139dc4bcd67c49b334c 1e51b	no	7					
<b>Warnings:</b>										
<b>Information:</b>										
19	NPL Documents	Crooke_Basic_Principals_Antisense_Thera_2.pdf	11863051 41a16711c887c940e7776e804490267a147 30855	no	50					
<b>Warnings:</b>										
<b>Information:</b>										
20		OA_Response_2010-03-15_FINAL.pdf	221268 2d7c2f83be5590eb93640f6c4914dedbcc4 888a4	yes	33					
	<b>Multipart Description/PDF files in .zip description</b>									
	<b>Document Description</b>			<b>Start</b>	<b>End</b>					
	Amendment/Req. Reconsideration-After Non-Final Reject			1	1					
	Claims			2	11					
	Applicant Arguments/Remarks Made in an Amendment			12	33					
<b>Warnings:</b>										
<b>Information:</b>										
21	Extension of Time	EOT_OA_Response_2010-03-15_signed.pdf	70299 293d8d3783ad7d91ae0b6cb3ac99b28174 6dd4bb	no	2					
<b>Warnings:</b>										
<b>Information:</b>										
22	Fee Worksheet (PTO-875)	fee-info.pdf	32001 82e2ac095ff5f01ee13cf4c11d8942e58e1f cba	no	2					
<b>Warnings:</b>										
<b>Information:</b>										
<b>Total Files Size (in bytes):</b>				62213490						

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.